Press Releases

Conference Call & Webcast Scheduled for Thursday, December 5th at 11:00am Eastern Time GAITHERSBURG, Md. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the

Conference Call & Webcast Scheduled for Thursday, November 14, at 8:30am Eastern Time GAITHERSBURG, Md. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2019 and

GAITHERSBURG, Md. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September

GAITHERSBURG, Md. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:           H.C.

GAITHERSBURG, Md. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris , M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker , who resigned June 30, 2019 to continue her

Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine GAITHERSBURG, Md. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and

Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time GAITHERSBURG, Md. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2019

GAITHERSBURG, Md. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019

GAITHERSBURG, Md. , July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc. , including the product candidate ALT-801, a potent GLP-1/Glucagon receptor

Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, inflammation and fibrosis compared to leading NASH candidates in established preclinical models Altimmune plans to advance the drug